AnandBKarnadMD

Oncology • San Antonio, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Karnad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Karnad's full profile

Already have an account?

Office
7979 Wurzbach Road
San Antonio, TX 78229
Phone+1 210-450-1143

Fax+1 210-450-0407
Is this information wrong?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 1982 - 1984
Madras Medical CollegeClass of 1981

Certifications & Licensure

TX State Medical License 2004 - 2025
TN State Medical License 1984 - 2004
GA State Medical License 1983 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy Start of enrollment: 2012 Feb 01
Terminated
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned.
Chase V West, Matthew J Butler, Supreet Kaur, Elizabeth Bowhay-Carnes, Anand B Karnad> ;JCO Oncology Practice. 2024 Jan 1
9 citations
Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
Chen Chen, Shujie Zhao, Xiangru Zhao, Lin Cao, Anand Karnad, Addanki P Kumar, James W Freeman> ;Cell Death & Disease. 2022 Aug 5
43 citations
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P. Collins, Paolo Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fi...> ;The Lancet. Haematology. 2021 Jun 1
1458 citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a ...
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Baste, Prakash Neupane, Åse Bratland, Tho...> ;Lancet. 2019 Nov 23
22 citations
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
, , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2018 Dec 15
675 citations
The biology and role of CD44 in cancer progression: Therapeutic implications
Chen Chen, Shujie Zhao, Anand B. Karnad, James W. Freeman> ;Journal of Hematology & Oncology. 2018 May 10
58 citations
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a r...
Roy S. Herbst, Mary W. Redman, Edward S. Kim, Thomas J. Semrad, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Ana...> ;The Lancet. Oncology. 2018 Jan 1
25 citations
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Kevin R. Kelly, Alex Mejia, Avvaru N. Suhasini, An Ping Lin, John G. Kuhn, Anand B. Karnad, Steven D. Weitman, Ricardo C.T. Aguiar> ;Clinical Cancer Research. 2017 Mar 1
4 citations
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Christos Fountzilas, Selena Juarez Stuart, Brian Hernandez, Elizabeth Bowhay-Carnes, Joel E. Michalek, John Sarantopoulos, Anand B. Karnad, Sukeshi R. Patel, Steven D....> ;Investigational New Drugs. 2017 Jan 19
33 citations
The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis
Tracy A. Battaglia, Julie S. Darnell, Naomi Y. Ko, Fred Snyder, Electra D. Paskett, Kristen J. Wells, Elizabeth M. Whitley, Jennifer J. Griggs, Anand B. Karnad, Heathe...> ;Breast Cancer Research and Treatment. 2016 Jul 18
98 citations
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Shujie Zhao, Chen Chen, Katherine Chang, Anand B. Karnad, Jaishree Jagirdar, Addanki P. Kumar, James W. Freeman> ;Clinical Cancer Research. 2016 Nov 15
15 citations
Association Between the Number of Suppliers for Critical Antineoplastics and Drug Shortages: Implications for Future Drug Shortages and Treatment.
Helen Parsons, Susanne Schmidt, Anand B. Karnad, Yuanyuan Liang, Mary Jo Pugh, Erin R. Fox> ;Journal of Oncology Practice. 2016 Feb 2
8 citations
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.
Chul S. Ha, Joel E. Michalek, Richard M Elledge, Kevin R. Kelly, Suthakar Ganapathy, Su Hang, Carol A. Jenkins, Athanassios Argiris, Ronan T. Swords, Tony Yuen Eng, An...> ;Molecular Oncology. 2016 Jan 1
16 citations
Use of Milestones and Development of Entrustable Professional Activities in 2 Hematology/Oncology Training Programs
Nathan M. Shumway, Jennifer Jill Dacus, Kate Lathrop, Elizabeth P. Hernandez, Maria Miller, Anand B. Karnad> ;Journal of Graduate Medical Education. 2015 Mar 2
44 citations
Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.
Katherine Chang, Anand B. Karnad, Shujie Zhao, James W. Freeman> ;Oncotarget. 2015 Feb 23
6 citations
Breast cancer treatment delays in a majority minority community: is there a difference?
Helen Parsons, Kate Lathrop, Susanne Schmidt, Marcela Mazo-Canola, Jessica Trevino-Jones, Heather Speck, Anand B. Karnad> ;Journal of Oncology Practice. 2015 Mar 1
14 citations
Hispanic Accrual on Randomized Cancer Clinical Trials: A Call to Arms
Alberto Parra, Anand B. Karnad, Ian M. Thompson> ;Journal of Clinical Oncology. 2014 Jun 20
24 citations
Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives
Patricia Chalela, Lucina Suarez, Edgar Munoz, Kipling J. Gallion, Brad H. Pollock, Steven D. Weitman, Anand B. Karnad, Amelie G. Ramirez> ;Journal of Community Medicine & Health Education. 2014 Apr 24
4 citations
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials
Sukeshi R. Patel, Anand B. Karnad, Norma S. Ketchum, Bradley H Pollock, John Sarantopoulos, Steven D. Weitman, Devalingam Mahalingam> ;Journal of Gastrointestinal Oncology. 2014 Apr 18
WTAP is a novel oncogenic protein in acute myeloid leukemia.
Bansal, H.,Yihua, Q.,Iyer, S. P.,Ganapathy, S.,Proia, D.,Penalva, L. O.,Uren, P. J.,Suresh, U.,Carew, J. S.,Karnad, A. B.,Weitman, S.,Tomlinson, G. E.,Rao, M. K.,Kornb...> ;Leukemia. 2014 Jan 15
17 citations
An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Resear...
Julie H. Rowe, Sukeshi R. Patel, Marcela Mazo-Canola, Alberto Parra, Martin Goros, Joel E. Michalek, Kevin R. Kelly, Steven D. Weitman, Anand B. Karnad> ;Journal of Geriatric Oncology. 2014 Jan 1
10 citations
The Development of a Minority Recruitment Plan for Cancer Clinical Trials.
Monica Trevino, Susan S. Padalecki, Anand B. Karnad, Alberto Parra, Steve Weitman, Melissa Nashawati, Brad H. Pollock, Amelie G. Ramirez, Ian M. Thompson> ;Journal of Community Medicine & Health Education. 2013 Sep 1
57 citations
Beneficial Effects of a Combined Navigator/Promotora Approach for Hispanic Women Diagnosed with Breast Abnormalities
Donald J. Dudley, Joan Drake, Jennifer Quinlan, Alan E.C. Holden, Pam Saegert, Anand B. Karnad, Amelie G. Ramirez> ;Cancer Epidemiology, Biomarkers & Prevention. 2012 Oct 1
Phase I trials in patients with salivary gland cancers (SGCs): The Cancer Therapy and Research Center (CTRC) experience.
Madhusudanannair V, Medina G, Lee S, Mita MM, Karnad AB> ;J. Clin. Oncol.. 2011-05-20
84 citations
Common toxicities of mammalian target of rapamycin inhibitors.
Scott A. Soefje, Anand B. Karnad, Andrew Brenner> ;Targeted Oncology. 2011 Apr 16
Join now to see all

Abstracts/Posters

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
Anand Karnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Mesa Departing March 2023December 12th, 2022
FDA Approves Immunotherapy Drug as First-Line Cancer TreatmentNovember 11th, 2016
Battling Cancer with ImmunotherapyNovember 11th, 2016

Grant Support

Protocol Review And Monitoring SystemNational Cancer Institute2009–2011
Clinical Trial: A PH II Study Of CNTO 328 Antibody Against IL-6 In PTS With PROSNational Center For Research Resources2008